We had the great pleasure of meeting with Stephanie Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss the HALO long term extension study investigating long term efficacy and tolerability of fremanezumab in patients with episodic and chronic migraine.
The abstract ‘Clinically Meaningful Responses to Fremanezumab Treatment in Episodic and Chronic Migraine over up to 15 Months’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
Questions:
- What is the rationale for continued analyses and extension studies of the fremanezumab clinical trial programs? (0:20)
- What has the HALO long term study taught us about the long term efficacy and tolerability of fremanezumab in patients with episodic and chronic migraine? (1:29)
- Could you tell us a little about the current post hoc analysis and what it has shown us in terms of clinically meaningful responses to treatment? (3:00)
Disclosures: Stephanie Nahas has been on the advisory board for Allergen/AbbVie, Zosano, Nesos Corp (formerly Vorso Corp); speaker for Allergan/AbbVie, Amgen/Novartis, Biohaven, Eli Lilly, Impel, Nesos Corp (formerly Vorso Corp), and has received clinical trial principal investigator support for Teva. Stephanie Nahas is also on the editorial board for Springer (Current Pain and Headache Reports), Wolters-Kluwer (UpToDate), and Neurology Learning Network.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021.
